Autologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)

N/A

Report date: 2024/12/20 14:57:49

Base Information

Drug NameAutologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)

Drug Alias Nameautologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector(Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)GMCN-508A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionAnti-CD34

TargetsHematopoietic progenitor cell antigen CD34

Therapy Area/Indicationsalpha-Thalassemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesZhongji Zhiyao (Nanjing) Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesZhongji Zhiyao (Nanjing) Biotechnology Co Ltd

Inactive CompaniesN/A

Active Indicationsalpha-Thalassemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A